RCUS

Arcus Biosciences, Inc.

17.30 USD
+0.52 (+3.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcus Biosciences, Inc. stock is up 17.85% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 May’s closed higher than April. In the last 9 Unusual Options Trades, there were 8 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Mar 16:47 19 Jul, 2024 20.00 CALL 250 91
18 Apr 15:05 17 May, 2024 12.50 CALL 1000 970
18 Apr 16:03 17 May, 2024 12.50 CALL 526 970
19 Apr 14:24 17 May, 2024 12.50 CALL 1000 2337
19 Apr 14:40 17 May, 2024 12.50 CALL 107 2337
19 Apr 14:46 17 May, 2024 12.50 CALL 116 2337
19 Apr 14:52 17 May, 2024 12.50 CALL 800 2337
19 Apr 14:53 17 May, 2024 12.50 CALL 900 2337
19 Apr 19:43 17 May, 2024 15.00 PUT 200 44

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.